Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2011-01-04
2011-01-04
Chernyshev, Olga N (Department: 1649)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S012200, C424S184100, C424S185100, C424S198100, C530S350000, C530S399000
Reexamination Certificate
active
07863247
ABSTRACT:
The invention relates to methods for reducing a condition associated with fetal alcohol syndrome in a subject who is exposed to alcohol in utero with an ADNF polypeptide (e.g, ADNF I polypeptides, ADNF III polypeptides, or mixtures of ADNF I and ADNF III polypeptides). In one embodiment, the present invention relates to methods for reducing a condition associated with fetal alcohol syndrome in a subject who is exposed to alcohol in utero with a mixture of ADNF I and ADNF III polypeptides. The present invention further relates to methods for reducing neuronal cell death by contacting neuronal cells with a mixture of ADNF I and ADNF III polypeptides. Still further, the present invention relates to a pharmaceutical composition comprising a mixture of ADNF I and ADNF III polypeptides.
REFERENCES:
patent: 5767240 (1998-06-01), Brenneman et al.
patent: 6174862 (2001-01-01), Brenneman
patent: 6613740 (2003-09-01), Gozes et al.
patent: 6649411 (2003-11-01), Gozes et al.
patent: 7264947 (2007-09-01), Gozes et al.
patent: 7452867 (2008-11-01), Gozes et al.
patent: 2004/0235747 (2004-11-01), Gozes et al.
patent: 2007/0054847 (2007-03-01), Gozes et al.
patent: 2009/0124543 (2009-05-01), Gozes et al.
patent: 2009/0137469 (2009-05-01), Gozes et al.
patent: 2009/0170780 (2009-07-01), Gozes et al.
patent: WO 92/18140 (1992-10-01), None
patent: WO 96/11948 (1996-04-01), None
patent: WO 98/35042 (1998-08-01), None
patent: WO 00/53217 (2000-09-01), None
Roth et al., 1999, Ann. Rev. Biomed. Eng., 01, pp. 265-297.
Welsh, 1999, Current Opinion in Mol. Therapeutics, 1 (4), pp. 464-470.
Bassan, M. et al. “Complete Sequence of a Novel ProteinContaining a Femtomolar-Activity-Dependent Neuroprotective Peptide.”Journal of Neurochemistry72:1283-1293 (1999).
Bassan, M. et al. “VIP-Induced Mechanism of Neuroprotection: The Complete Sequence of a Femtomolar-Acting Activity-Dependent Neuroprotective Protein.”Regulatory Peptides, 71(2): , Aug. 15, 1997.
Beni-Adani, L. et al. “Activity-Dependent Neurotrophic Protein is Neuroprotective in a Mouse Model of Closed Head Injury.” Society for Neuroscience, 28thAnnual Meeting, Los Angeles, CA, Nov. 7-12, 1998.Abstracts23(1):1043 (1998).
Brenneman et al. “Neuronal Cell Killing by the Envelope Protein of HIV and Its Prevention by Vasoactive Intestinal Peptide.”Nature335:636 (1988).
Brenneman et al. “N-Methyl-D-Aspartate Receptors Influence Neuronal Survival in Developing Spinal Cord Cultures”Dev. Brain Res.51:63 (1990).
Brenneman, D.C. and Gozes, I. “A Femtomolar-Acting Neuroprotective Peptide.”Journal of Clinical Investigation97:229-230 (1996).
Brenneman, D.E. et al. “Activity-Dependent neutotrophic Factor: Structure-Activity Relationships of Femtomolar-Acting Peptides.”Journal of Pharmacology and Experimental Therapeutics285: 619-627 (1998).
Brenneman, D.E. et al. “Identification of a Nine Amino Acid Core Peptide from Activity Dependent Neurotrophic Factor I.” Society for Neuroscience, 27thAnnual Meeting, New Orleans, LA, Oct. 25-30, 1997.Abstracts23(2): 2250 (1997).
Davidson, A. et al. “Protection Against Developmental Retardation and Learning Impairments in Apolipoprotein E-Deficient Mice by Activity-Dependent Femtomolar-Acting Peptides.” Society for Neuroscience, 27thAnnual Meeting, New Orleans, LA, Oct. 25-30, 1997.Abstracts23(2)2250 (1997).
Dibbern, D.A., Jr. et al. “Inhibition of Murine Embryonic Growth by Human Immunodeficiency Virus Envelope Protein and Its Prevention by Vasoactive Intestinal Peptide and Activity-Dependent Neurotrophic Factor.”Journal of Clinical Investigation99: 2837-2841 (1997).
Giladi, E. “Protection Against Developmental and Learning Impairments in Apolipoprotein E-Deficient Mice by Activity-Dependent Femtomolar-Acting Peptides.”Neuroscience LettersSupplement 48 S1-S60, p. S19 (1997).
Glazner, G.W. et al. “A 9 Amino Acid Peptide Fragment of Activity-Dependent Neurotrophic Factor (ADNF) Protects Neurons from Oxidative Stress-Induced Death.” Society for Neuroscience, 27thAnnual Meeting, New Orleans, LA, Oct. 25-30, 1997.Abstracts23(2)2249 (1997).
Glazner, G.W. et al. “Activity Dependent Neurotrophic Factor: A Potent Regulator of Embryonic Growth.”Anat. Embryol.200:65-71 (1999).
Gozes I. et al. “Antiserum to Activity-Dependent Neurotrophic Factor Produces Neuronal Cell Death in CNS Cultures: Immunological and Biological Specificity.”Developmental Brain Research99:167-175 (1997).
Gozes, I. and Brenneman, D.E. “Activity-Dependent Neurotrophic Factor (ADNF).”Journal of Molecular Neuroscience7:235-244 (1996).
Gozes, I. et al. A Femtomolar-Acting Activity-Dependent Neuroprotective Protein (ADNP).Neuroscience LettersSupplement 48 S1-S60, p. S21 (1997)-.
Gozes, I. et al. “Protection Against Developmental Retardation in Apolipoprotein E-Deficient Mice by a Fatty neuropeptide: Implications for Early Treatment of Alzheimer's Disease.”Journal of Neurobiology33:329-342 (1997).
Gozes, I. et al. “Stearyl-Norleucine-Vasoactive Intestinal Peptide (VIP): A Novel VIP Analog for Noninvasive Impotence Treatment.”Endocrinology134: 2125 (1994).
Gozes, I. et al. “Superactive Lipophilic Peptides Discriminate Multiple Vasoactive intestinal Peptide Receptors.”Journal of Pharmacology and Experimental Therapeutics27:3161-167 (1995).
Gozes, I. et al. “The cDNA Structure of a Novel Femtomolar-Acting Neuroprotective Protein: Activity-Dependent-Neurotrophic Factor III (ADNFIII).” Society for Neuroscience, 27thAnnual Meeting, New Orleans, LA, Oct. 25-30, 1997.Abstracts23(2):2250 (1997).
Gozes, I. et al. “Neuroprotective Strategy for Alzheimer Disease: Intranasal Administration of a Fatty Neuropeptide.”Proc. Natl. Acad. Sci. USA93:427-432 (1996).
Gressens, P. et al. “Growth Factor Function of Vasoactive Intestinal Peptide in Whole Cultured Mouse Embryos.”Nature362:155-58 (1993).
Hannigan, J.H. and Berman, R.F. “Amelioration of Fetal Alcohol-Related Neurodevelopmental Disorders in Rats: Exploring Pharmacological and Environmental Treatments.”Neurotoxicol.&Teratol. 22(1):103-111 (2000).
Hill, J.M. et al. “Learning Impairment in Adult Mice Produced by Early Embryonic Administration of Antiseum to Activity-Dependent Neurotrophic Factor (ADNF).” Society for Neuroscience, 27thAnnual Meeting, New Orleans, LA, Oct. 25-30, 1997.Abstracts23(2):2250 (1997).
Lilling, G. et al. “Inhibition of Human Neuroblastoma Growth by a Specific VIP Antagonist.”Journal of Molecular Neuroscience5: 231-239 (1995).
Mahato et al. “Development of Targeted Delivery Systems for Nucleic Acid Drugs.”J. of Drug Targeting4(6):337-357 (1997).
McKune, S.K. et al. “Localization of mRNA for Activity-Dependent Neurotrophic Factor III (ADNF III) in mouse Embryo and Adult CNS.” Society for Neuroscience, 27thAnnual Meeting, New Orleans, LA, Oct. 25-30, 1997.Abstracts23(2):2249 (1997).
Nelbock, P. et al. A cDNA for a Protein that Interacts with the Human Immunodeficiency Virus Tat Transactivator.Science, 248:1650-1653 (1990).
Oberdoester, J. et al. “The Effects of Ethanol on Neuronal Cell Death: Implication for the Fetal Alcohol Syndrome.”FASEB Journal12(4):A134 (Mar. 17, 1998).
Pelsman, A. et al. “In Vitro Degeneration of Down Syndrome neurons is Prevented by Activity-Dependent Neurotrophic Factor-Derived Peptides.” Society for Neuroscience, 28THAnnual Meeting, Los Angeles, CA, Nov. 7-12, 1998.Abstracts24:1044 (1998).
Skolnick, J. and Fetrow, J.S. “Form Genes to Protein Structure and Function: Novel Applications of Computational Approaches in the Genomic Era.”Trends in Biotech. 18(1):34-39 (2000).
Smith, A.E. “Viral Vectors in Gene Therapy.”Ann. Rev.Microbiol. 49:807-838 (1995).
Spinney, L. “New Peptides Prevent Brain Damage.”Molecular Medicine Today5(7):282 (Jul. 1999).
Spong et al.
Bassan Merav
Brenneman Douglas E.
Gozes Illana
Spong Catherine Y.
Zamostiano Rachel
Chernyshev Olga N
Ramot-University Authority for Applied Research and Development
Townsend and Townsend / and Crew LLP
LandOfFree
Prevention of fetal alcohol syndrome and neuronal cell death... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Prevention of fetal alcohol syndrome and neuronal cell death..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Prevention of fetal alcohol syndrome and neuronal cell death... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2718034